Discovery of pyrimidyl-5-hydroxamic acids as new potent histone deacetylase inhibitors

被引：18

作者：

Angibaud, P

Arts, J

Van Emelen, K

Poncelet, V

Pilatte, I

Roux, B

Van Brandt, S

Verdonck, M

De Winter, H

Ten Holte, P

Marien, A

Floren, W

Janssens, B

Van Dun, J

Aerts, A

Van Gornpel, J

Gaurrand, S

Queguiner, L

Argoullon, JM

Van Hijfte, L

Freyne, E

Janicot, M

机构：

[1] Johnson & Johnson Pharmaceut Res & Dev, Dept Med Chem, F-27106 Reuil, France

[2] Oncol Discovery Res, B-2340 Beerse, Belgium

[3] Dept Med Chem, B-2340 Beerse, Belgium

[4] Preclin Pharmacokinet, B-2340 Beerse, Belgium

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2005年 / 40卷 / 06期

关键词：

histone deacetylase; hydroxamic acid; anticancer agents;

D O I：

10.1016/j.ejmech.2005.01.008

中图分类号：

R914 [药物化学];

学科分类号：

100701 [药物化学];

摘要：

A series of pyrimidyl-5-hydroxamic acids was prepared for evaluation as inhibitors of histone deacetylase (HDAC). Amino-2-pyrimidinyl can be used as a linker to provide HDAC inhibitors of good enzymatic potency. (c) 2005 Elsevier SAS. All rights reserved.

引用

页码：597 / 606

页数：10

共 23 条

[1]

ANGIBAUD RP, 2003, Patent No. 03076430

[2]

p21WAF1 is required for butyrate-mediated growth inhibition of human colon cancer cells [J].